Subscription Required

Only paid subscribers* to Specialty Pharmacy News can access this Web portal with three years of back issues, searchable article archives and other valuable resources.

Subscribers to Specialty Pharmacy News receive

  • 12 monthly issues packed with news and strategies on this increasingly vital sector in health business, delivered First Class by U.S. Mail and electronically (optional),
  • E-News Alerts whenever important news breaks, and
  • Access to a subscriber-only Web page with:
    • Searchable archives of past articles,
    • Convenient library with PDFs of back issues,
    • Recent stories of interest grouped for convenient reading
    • Bonus reports for subscribers, and
    • Regular postings from your editor.
View a sample and get more information
July 2017

Recent Stories

From Specialty Pharmacy News - Almost eight months after a provision in the 21st Century Cures Act took effect, many home infusion providers are finding themselves under water, while some are not taking on new Medicare Part B patients. But a recently introduced bill, which has bipartisan support, could help plug a reimbursement gap that’s causing issues within the industry. Read more

Following years of scrutiny over whether the 340B Drug Pricing Program truly… Read more

In a closely watched case, the U.S. Supreme Court issued a ruling… Read more

Vertex Pharmaceuticals Inc. recently added Maxor National Pharmacy Services, LLC to its… Read more

From the Editor

Welcome to your Specialty Pharmacy News subscriber-only Web page

Be sure to visit often, for PDFs of issues, archives of articles and data, and more!

Please e-mail me with your comments on the last issue of Specialty Pharmacy News, story ideas for future issues, or any other suggestions you have that can make the newsletter more useful for you.

August 2, 2017
CMS Unveils 2018 Standard Control Formulary

CMS will remove 17 drugs across 10 classes from its Standard Control Formulary in 2018, will launch Transform Value program in oncology, obesity, respiratory areas

July 31, 2017
Express Scripts Releases 2018 National Preferred Formulary

Express Scripts releases 2018 National Preferred Formulary, adding 64 drug exclusions for a total of 159. PBM says it expects employers who use the NPF will save an additional $2.5 billion next year

July 24, 2017
Second Biosimilar Remicade Launches

Samsung Bioepis’ Renflexis (infliximab-abda) is now available in the U.S. from Merck at a 35% discount to the wholesale acquisition cost of its reference drug, Remicade. Renflexis is second biosimilar Remicade after Inflectra (infliximab-dyyb)

It's quick and easy to sign up for FREE access to!

Why do I need to register?